You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Claims for Patent: 8,324,283


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,324,283
Title:Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor agonist; and (b) a sugar alcohol.
Inventor(s): Oomura; Tomoyuki (Oita, JP), Pudipeddi; Madhusudhan (Edison, NJ), Ruegger; Colleen (Morris Plains, NJ), Royce; Alan E (Saylorsburg, PA), Sasaki; Masaki (Oita, JP), Tamura; Tokuhiro (Fukuoka, JP)
Assignee: Novartis AG (Basel, CH) Mitsubishi Pharma Corporation (Osaka, JP)
Application Number:12/189,323
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,324,283
Patent Claims: 1. A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor agonist which is selected from 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl]propyl-1,3-propane-diol or 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]propyl-1,3-propane- -diol, 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-ethyl-1,3-pr- opane-diol, and its phosphates or a pharmaceutically acceptable salt thereof; and (b) a sugar alcohol.

2. The composition of claim 1, wherein the salt is the hydrochloride.

3. A composition according to claim 1, wherein the sugar alcohol is a non-hygroscopic sugar alcohol or a mixture thereof.

4. A composition according to claim 1, wherein the sugar alcohol comprises mannitol.

5. A composition according to claim 1, further comprising a lubricant.

6. A composition according to claim 5, wherein the lubricant comprises magnesium stearate.

7. A composition according to claim 1, comprising 0.01 to 20% by weight of the S1P receptor agonist.

8. A composition according to claim 7, comprising 0.5 to 5% by weight of the S1P receptor agonist.

9. A composition according to claim 1, comprising 75 to 99.99% by weight of the sugar alcohol.

10. A composition according to claim 9, comprising 90 to 99.5% by weight of the sugar alcohol.

11. A composition according to claim 5, comprising 0.01 to 5% by weight of the lubricant.

12. A composition according to claim 11, comprising 1.5 to 2.5% by weight of the lubricant.

13. A composition according to claim 1, wherein the S1P receptor agonist is micronized.

14. A composition according to claim 13, wherein the S1P receptor agonist is pre-screened with a 400 to 500 .mu.m mesh screen.

15. A composition according to claim 1, in the form of a tablet.

16. A composition according to claim 1 in the form of a capsule.

17. A method of treating organ or tissue transplant rejection, graft versus host disease, an autoimmune disease, an inflammatory condition, viral myocarditis or a viral disease caused by viral myocarditis in a subject in need thereof, comprising administering to said subject a pharmaceutical composition according to claim 1.

18. A method according to claim 17, wherein the disease or condition that is treated is multiple sclerosis.

19. A solid pharmaceutical composition suitable for oral administration, comprising mannitol and 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

20. A composition according to claim 19, further comprising a lubricant.

21. A composition according to claim 20, wherein the lubricant comprises magnesium stearate.

22. A composition according to claim 19, wherein the compound 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, or a pharmaceutically acceptable salt thereof, is present in an amount of 0.5 to 5% by weight, based on the total weight of the composition.

23. A composition according to claim 19, wherein mannitol is present in an amount of 90 to 99.5% by weight, based on the total weight of the composition.

24. A composition according to claim 19, wherein the lubricant is present in an amount of 1.5 to 2.5% by weight, based on the total weight of the composition.

25. A composition according to claim 19, wherein said composition is in the form of a tablet.

26. A composition according to claim 19, wherein said composition is in the form of a capsule.

27. A composition according to claim 19, wherein the mannitol has a mean particle size of 100 to 300 .mu.m.

28. A composition according to claim 27, wherein the mannitol has a mean particle size of 150 to 250 .mu.m.

29. A composition according to claim 19, wherein the mannitol has a bulk density of 0.4 to 0.6 g/mL.

30. A composition according to claim 29, wherein the mannitol has a bulk density of 0.45 to 0.55 g/mL.

31. A composition according to claim 19, wherein the mannitol has a single point surface area of 1 m.sup.2/g to 7 m.sup.2/g.

32. A pharmaceutical composition according to claim 1, wherein the S1P receptor agonist is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.